PL191618B1 - Związki azabenzimidazolowe, środki farmaceutyczne zawierające te związki, sposób wytwarzania i zastosowania tych związków - Google Patents

Związki azabenzimidazolowe, środki farmaceutyczne zawierające te związki, sposób wytwarzania i zastosowania tych związków

Info

Publication number
PL191618B1
PL191618B1 PL339744A PL33974498A PL191618B1 PL 191618 B1 PL191618 B1 PL 191618B1 PL 339744 A PL339744 A PL 339744A PL 33974498 A PL33974498 A PL 33974498A PL 191618 B1 PL191618 B1 PL 191618B1
Authority
PL
Poland
Prior art keywords
protein kinase
raf
compounds
compound
cancer
Prior art date
Application number
PL339744A
Other languages
English (en)
Polish (pl)
Other versions
PL339744A1 (en
Inventor
Gerald Macmahon
Heinz Weinberger
Bernhard Kutscher
Harald App
Original Assignee
Zentaris Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zentaris Gmbh filed Critical Zentaris Gmbh
Publication of PL339744A1 publication Critical patent/PL339744A1/xx
Publication of PL191618B1 publication Critical patent/PL191618B1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
PL339744A 1997-09-26 1998-09-23 Związki azabenzimidazolowe, środki farmaceutyczne zawierające te związki, sposób wytwarzania i zastosowania tych związków PL191618B1 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6014597P 1997-09-26 1997-09-26
PCT/US1998/019973 WO1999016438A1 (en) 1997-09-26 1998-09-23 Azabenzimidazole-based compounds for modulating serine/threonine protein kinase function

Publications (2)

Publication Number Publication Date
PL339744A1 PL339744A1 (en) 2001-01-02
PL191618B1 true PL191618B1 (pl) 2006-06-30

Family

ID=22027657

Family Applications (1)

Application Number Title Priority Date Filing Date
PL339744A PL191618B1 (pl) 1997-09-26 1998-09-23 Związki azabenzimidazolowe, środki farmaceutyczne zawierające te związki, sposób wytwarzania i zastosowania tych związków

Country Status (27)

Country Link
US (2) US6093728A (enExample)
EP (1) EP1017384B1 (enExample)
JP (1) JP2001517699A (enExample)
KR (1) KR100547929B1 (enExample)
CN (1) CN1167420C (enExample)
AR (1) AR017266A1 (enExample)
AT (1) ATE281834T1 (enExample)
AU (1) AU748849B2 (enExample)
BG (1) BG64784B1 (enExample)
BR (1) BR9812682A (enExample)
CA (1) CA2305370C (enExample)
DE (1) DE69827516T2 (enExample)
DK (1) DK1017384T3 (enExample)
ES (1) ES2230719T3 (enExample)
HU (1) HUP0004024A3 (enExample)
IL (4) IL135109A0 (enExample)
NO (1) NO325663B1 (enExample)
NZ (2) NZ503432A (enExample)
PL (1) PL191618B1 (enExample)
PT (1) PT1017384E (enExample)
RU (1) RU2230553C2 (enExample)
SK (1) SK285357B6 (enExample)
TR (1) TR200001546T2 (enExample)
TW (1) TW581815B (enExample)
UA (1) UA72448C2 (enExample)
WO (1) WO1999016438A1 (enExample)
ZA (1) ZA988797B (enExample)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060142236A1 (en) * 1994-05-31 2006-06-29 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of raf gene expression
US6911462B2 (en) * 1998-05-22 2005-06-28 Avanir Pharmaceuticals Benzimidazole compounds for regulating IgE
US6919366B2 (en) * 1998-05-22 2005-07-19 Avanir Pharmaceuticals Benzimidazole derivatives as modulators of IgE
US6384049B1 (en) * 2000-05-25 2002-05-07 The Procter & Gamble Company Cancer treatment
JP2004528304A (ja) * 2001-03-12 2004-09-16 アバニール・ファーマシューティカルズ ＩｇＥを調節し、細胞増殖を阻害するためのベンゾイミダゾール化合物
TW200304820A (en) * 2002-03-25 2003-10-16 Avanir Pharmaceuticals Use of benzimidazole analogs in the treatment of cell proliferation
AU2003270426A1 (en) 2002-09-12 2004-04-30 Avanir Pharmaceuticals PHENYL-INDOLE COMPOUNDS FOR MODULATING IgE AND INHIBITING CELLULAR PROLIFERATION
TWI276631B (en) * 2002-09-12 2007-03-21 Avanir Pharmaceuticals Phenyl-aza-benzimidazole compounds for modulating IgE and inhibiting cellular proliferation
AU2004263190A1 (en) * 2003-08-08 2005-02-17 Avanir Pharmaceuticals Selective pharmacologic inhibition of protein trafficking and related methods of treating human diseases
GB0423554D0 (en) 2004-10-22 2004-11-24 Cancer Rec Tech Ltd Therapeutic compounds
EP1962892A4 (en) 2005-11-22 2011-10-12 Univ South Florida INHIBITION OF CELL PROLIFERATION
WO2007125330A1 (en) 2006-04-26 2007-11-08 Cancer Research Technology Limited Imidazo[4, 5-b]pyridin-2-one and oxazolo[4, 5-b]pyridin-2-one compounds and analogs thereof as cancer therapeutic compounds
MX2009004077A (es) 2006-10-19 2009-05-05 Signal Pharm Llc Compuestos de heteroarilo, composiciones de los mismos, y su uso como inhibidores de proteina cinasas.
US8748371B2 (en) * 2007-02-28 2014-06-10 Yeda Research And Development Co. Ltd. Nuclear targeting sequences
PE20090370A1 (es) * 2007-06-05 2009-04-30 Takeda Pharmaceutical Derivados de heterociclo fusionado como inhibidores de quinasa
WO2009025358A1 (ja) 2007-08-23 2009-02-26 Takeda Pharmaceutical Company Limited 複素環化合物およびその用途
JP5350247B2 (ja) 2007-08-29 2013-11-27 武田薬品工業株式会社 複素環化合物およびその用途
EA019974B1 (ru) 2007-12-19 2014-07-30 Кансер Рисерч Текнолоджи Лимитед 8-ЗАМЕЩЕННЫЕ ПИРИДО[2,3-b]ПИРАЗИНЫ И ИХ ПРИМЕНЕНИЕ
GB0807609D0 (en) 2008-04-25 2008-06-04 Cancer Rec Tech Ltd Therapeutic compounds and their use
WO2010025448A2 (en) * 2008-08-29 2010-03-04 University Of South Florida Inhibition of cell proliferation
US8110578B2 (en) 2008-10-27 2012-02-07 Signal Pharmaceuticals, Llc Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway
JP5579619B2 (ja) 2008-12-01 2014-08-27 武田薬品工業株式会社 複素環化合物およびその用途
JO3101B1 (ar) 2008-12-02 2017-09-20 Takeda Pharmaceuticals Co مشتقات بنزوثيازول كعوامل مضادة للسرطان
JP2012197231A (ja) * 2009-08-06 2012-10-18 Oncotherapy Science Ltd Ｔｔｋ阻害作用を有するピリジンおよびピリミジン誘導体
JP2013508456A (ja) 2009-10-26 2013-03-07 シグナル ファーマシューティカルズ， エルエルシー ヘテロアリール化合物の合成方法および精製方法
CN102906090B (zh) 2010-02-01 2015-06-24 癌症研究技术有限公司 1-(5-叔丁基-2-苯基-2h-吡唑-3-基)-3-[2-氟-4-(1-甲基-2-氧代-2,3-二氢-1h-咪唑并[4,5-b]吡啶-7-基氧基)-苯基]-脲和相关化合物及它们在治疗中的应用
US9493466B2 (en) 2011-10-19 2016-11-15 Signal Pharmaceuticals, Llc Treatment of cancer with TOR kinase inhibitors
ES2694413T3 (es) 2011-12-02 2018-12-20 Signal Pharmaceuticals, Llc Composiciones farmacéuticas de 7-(6-(2-hidroxipropan-2-il)piridin-3-il)-1-((trans)-4-metoxiciclohexil)-3,4-dihidropirazino [2,3-b]pirazin-2(1H)-ona, una forma sólida de la misma y métodos para su uso
CA2864905A1 (en) 2012-02-24 2013-08-29 Signal Pharmaceuticals, Llc Methods for treating non- small cell lung cancer using tor kinase inhibitor combination therapy
AU2013203714B2 (en) 2012-10-18 2015-12-03 Signal Pharmaceuticals, Llc Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity
HK1212207A1 (en) 2013-01-16 2016-06-10 西格诺药品有限公司 Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith
WO2014145852A2 (en) 2013-03-15 2014-09-18 Knopp Biosciences Llc Imidazo(4,5-b) pyridin-2-yl amides as kv7 channel activators
SG11201508527VA (en) 2013-04-17 2015-11-27 Signal Pharm Llc Pharmaceutical formulations, processes, solid forms and methods of use relating to 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl) pyridin-3-yl) -3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one
MX364101B (es) 2013-04-17 2019-04-12 Signal Pharm Llc Terapia de combinación que comprende un compuesto de dihidropirazino-pirazina y un antagonista de receptor de andrógenos para tratar cáncer de próstata.
HK1221174A1 (zh) 2013-04-17 2017-05-26 西格诺药品有限公司 用於治疗癌症的包括tor激酶抑制剂和5-取代喹唑啉酮化合物的组合疗法
EA030808B1 (ru) 2013-04-17 2018-09-28 СИГНАЛ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи ПРИМЕНЕНИЕ 1-ЭТИЛ-7-(2-МЕТИЛ-6-(1Н-1,2,4-ТРИАЗОЛ-3-ИЛ)ПИРИДИН-3-ИЛ)-3,4-ДИГИДРОПИРАЗИНО[2,3-b]ПИРАЗИН-2(1Н)-ОНА В ЛЕЧЕНИИ МУЛЬТИФОРМНОЙ ГЛИОБЛАСТОМЫ
HK1221150A1 (zh) 2013-04-17 2017-05-26 西格诺药品有限公司 用二氢吡嗪并-吡嗪类对癌症的治疗
WO2014172432A1 (en) 2013-04-17 2014-10-23 Signal Pharmaceuticals, Llc Combination therapy comprising a tor kinase inhibitor and a cytidine analog for treating cancer
CA2909579A1 (en) 2013-04-17 2014-10-23 Signal Pharmaceuticals, Llc Combination therapy comprising a tor kinase inhibitor and n-(3-(5-fluoro-2-(4-(2-methoxyethoxy)phenylamino)pyrimidin-4-ylamino)phenyl)acrylamide for treating cancer
CA3143529A1 (en) 2013-05-29 2014-12-04 Signal Pharmaceuticals, Llc Pharmaceutical compositions 0f 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino [2,3-b]pyrazin-2(1h)-one, a solid form thereof and methods of their use
WO2015040609A1 (en) 2013-09-17 2015-03-26 Yeda Research And Development Co. Ltd. Erk-derived peptides and uses thereof
GB201320732D0 (en) 2013-11-25 2014-01-08 Cancer Rec Tech Ltd Methods of chemical synthesis
GB201320729D0 (en) 2013-11-25 2014-01-08 Cancer Rec Tech Ltd Therapeutic compounds and their use
WO2015160880A1 (en) 2014-04-16 2015-10-22 Signal Pharmaceuticals, Llc SOLID FORMS COMPRISING 1-ETHYL-7-(2-METHYL-6-(1H-1,2,4-TRIAZOL-3-YL) PYRIDIN-3-YL)-3,4-DIHYDROPYRAZINO(2,3-b)PYRAZIN-2(1H)-ONE, AND A COFORMER, COMPOSITIONS AND METHODS OF USE THEREOF
US9718824B2 (en) 2014-04-16 2017-08-01 Signal Pharmaceuticals, Llc Solid forms comprising 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one, and a coformer, compositions and methods of use thereof
NZ714742A (en) 2014-04-16 2017-04-28 Signal Pharm Llc Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use
US9737535B2 (en) 2014-04-16 2017-08-22 Signal Pharmaceuticals, Llc Methods for treating cancer using TOR kinase inhibitor combination therapy comprising administering substituted pyrazino[2,3-b]pyrazines
KR20170024120A (ko) 2014-07-14 2017-03-06 시그날 파마소티칼 엘엘씨 치환된 피롤로피리미딘 화합물을 사용한 암의 치료방법, 이의 조성물
NZ629796A (en) 2014-07-14 2015-12-24 Signal Pharm Llc Amorphous form of 4-((4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7h-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3-methoxy-n-methylbenzamide, compositions thereof and methods of their use
WO2016040952A2 (en) 2014-09-12 2016-03-17 Knopp Biosciences Llc BENZOIMIDAZOL-1,2-YL AMIDES AS Kv7 CHANNEL ACTIVATORS
MY198676A (en) 2017-06-22 2023-09-15 Celgene Corp Treatment of hepatocellular carcinoma characterized by hepatitis b virus infection

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3590045A (en) * 1969-09-25 1971-06-29 Smith Kline French Lab Certain substituted imidazo (4,5-b)pyridines
BE788065A (fr) 1971-08-26 1973-02-26 Degussa Nouvelles aza-benzimidazoles et procede pour leur preparation
SE422799B (sv) 1975-05-28 1982-03-29 Merck & Co Inc Analogiforfarande for framstellning av 1,3-dihydroimidazo (4,5-b)pyridin-2-oner
ES473201A1 (es) * 1977-09-26 1979-03-16 Degussa Procedimiento para la preparacion de 7-azabencimidazoles
US5217999A (en) * 1987-12-24 1993-06-08 Yissum Research Development Company Of The Hebrew University Of Jerusalem Styryl compounds which inhibit EGF receptor protein tyrosine kinase
ES2064101T3 (es) * 1990-04-02 1995-01-16 Pfizer Compuestos de acido bencilfosfonico inhibidores de la quinasa de tirosina.
US5302606A (en) * 1990-04-16 1994-04-12 Rhone-Poulenc Rorer Pharmaceuticals Inc. Styryl-substituted pyridyl compounds which inhibit EGF receptor tyrosine kinase
WO1992020642A1 (en) * 1991-05-10 1992-11-26 Rhone-Poulenc Rorer International (Holdings) Inc. Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase
JPH06503095A (ja) * 1991-05-29 1994-04-07 ファイザー・インコーポレーテッド 三環式ポリヒドロキシ系のチロシンキナーゼ阻害薬
AU661533B2 (en) * 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
JPH08503450A (ja) * 1992-08-06 1996-04-16 ワーナー−ランバート・コンパニー 蛋白チロシンキナーゼを阻害し、かつ抗腫瘍特性を有する２−チオインドール（セレノインドール）および関連ジスルフィド（セレニド）
US5330992A (en) * 1992-10-23 1994-07-19 Sterling Winthrop Inc. 1-cyclopropyl-4-pyridyl-quinolinones
GB9226855D0 (en) * 1992-12-23 1993-02-17 Erba Carlo Spa Vinylene-azaindole derivatives and process for their preparation
US5582995A (en) 1993-06-11 1996-12-10 The General Hospital Corporation Methods of screening for compounds which inhibit the direct binding of Ras to Raf
JP2944048B2 (ja) * 1993-07-06 1999-08-30 フアイザー・インコーポレイテツド 二環式テトラヒドロピラゾロピリジン
US5645982A (en) * 1993-08-19 1997-07-08 Systemix, Inc. Method for screening potential therapeutically effective antiviral agents
GB9501567D0 (en) * 1995-01-26 1995-03-15 Pharmacia Spa Hydrosoluble 3-arylidene-2-oxindole derivatives as tyrosine kinase inhibitors
US5880141A (en) * 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease

Also Published As

Publication number Publication date
CN1167420C (zh) 2004-09-22
TW581815B (en) 2004-04-01
BG64784B1 (bg) 2006-04-28
EP1017384A1 (en) 2000-07-12
TR200001546T2 (tr) 2000-10-23
NZ503432A (en) 2002-11-26
JP2001517699A (ja) 2001-10-09
DE69827516D1 (de) 2004-12-16
EP1017384B1 (en) 2004-11-10
NO20001555D0 (no) 2000-03-24
AU748849B2 (en) 2002-06-13
SK4152000A3 (en) 2002-02-05
KR100547929B1 (ko) 2006-02-02
US20030181480A1 (en) 2003-09-25
IL135109A0 (en) 2001-05-20
PL339744A1 (en) 2001-01-02
AR017266A1 (es) 2001-09-05
NO20001555L (no) 2000-03-24
HK1032206A1 (en) 2001-07-13
IL135109A (en) 2007-07-04
ES2230719T3 (es) 2005-05-01
CA2305370A1 (en) 1999-04-08
US6855723B2 (en) 2005-02-15
PT1017384E (pt) 2005-03-31
IL158649A (en) 2006-12-10
IL158649A0 (en) 2004-05-12
CA2305370C (en) 2006-11-28
BR9812682A (pt) 2000-08-22
WO1999016438A1 (en) 1999-04-08
AU9578198A (en) 1999-04-23
RU2230553C2 (ru) 2004-06-20
HUP0004024A3 (en) 2001-10-29
CN1278172A (zh) 2000-12-27
US6093728A (en) 2000-07-25
NO325663B1 (no) 2008-07-07
SK285357B6 (sk) 2006-11-03
NZ517808A (en) 2003-07-25
DE69827516T2 (de) 2005-12-01
KR20010015623A (ko) 2001-02-26
ZA988797B (en) 1999-12-02
ATE281834T1 (de) 2004-11-15
UA72448C2 (en) 2005-03-15
DK1017384T3 (da) 2005-01-31
BG104356A (en) 2000-12-29
HUP0004024A2 (hu) 2001-04-28

Similar Documents

Publication Publication Date Title
PL191618B1 (pl) Związki azabenzimidazolowe, środki farmaceutyczne zawierające te związki, sposób wytwarzania i zastosowania tych związków
US6180631B1 (en) Methods of modulating serine/threonine protein kinase function with 5-azaquinoxaline-based compounds
US6204267B1 (en) Methods of modulating serine/thereonine protein kinase function with quinazoline-based compounds
MXPA00002910A (en) Azabenzimidazole-based compounds for modulating serine/threonine protein kinase function
CZ2000990A3 (cs) Způsob in vitro modulace funkce serin/threonin protein kinázy, způsob in vitro identifikace sloučenin pro tuto modulaci, sloučeniny na bázi azabenzimidazolu,jejich použití, způsob jejich výroby a farmaceutické kompozice

Legal Events

Date Code Title Description
LAPS Decisions on the lapse of the protection rights

Effective date: 20080923